[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565855":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":68,"collaborators":70,"id":73,"slug":10,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":10,"overallStatus":93,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TH-combination cohort",null,"L-T4+L-T3 combination according to local protocol.",[13],"Drug: Cytomel (liothyronine)",{"label":15,"type":10,"description":16,"interventionNames":17},"Levothyroxine cohort","L-T4 monotherapy according to local protocol.",[18],"Drug: Euthyrox (levothyroxine)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Euthyrox (levothyroxine)","Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight \u002F day.",[15],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Cytomel (liothyronine)","Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3.\n\nThe patients in this cohort recieve L-T4+L-T3 combination therapy. The L-T4 dose will be 2 μg × kg body weight \u002F day, equal to the dose in the other interventional arm. L-T3 will be added twice daily from the first day of combination treatment, in dosages gradually decreasing from 25 ug 2\u002Fday to 5 ug 2\u002Fday over a time span of 3 weeks after which L-T3 is stopped.",[9],[30],{"name":31,"affiliation":5,"role":32},"Wouter Zandee, MD\u002FPhD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Mirthe Links, BSc","CONTACT","+31 50 3610973","m.h.links@umcg.nl",{"name":31,"role":36,"phone":40,"phoneExt":10,"email":41},"+31 50 3613731","w.t.zandee@umcg.nl",[43,58],{"facility":44,"status":10,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University Medical Center Groningen (UMCG)","Groningen","Provincie Groningen","9700RB","Netherlands",{"type":50,"coordinates":51},"Point",[52,53],6.56667,53.21917,{"lat":53,"lon":52},[56],{"name":57,"role":36,"phone":37,"phoneExt":10,"email":38},"Mirthe Links, Bsc",{"facility":59,"status":10,"city":60,"state":10,"zip":10,"country":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Radboud University Nijmegen","Nijmegen",{"type":50,"coordinates":62},[63,64],5.85278,51.8425,{"lat":64,"lon":63},[67],{"name":57,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[71],{"name":72,"class":6},"Radboud University Medical Center","100565855",false,"NCT06647602","Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy","THRIVE","Inclusion Criteria:\n\n* Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)\n* Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).\n* Prepared for RAI-therapy with TH-withdrawal\n* Patients must be fit to adhere to the study protocol\n* Patients must be able to read and understand the Dutch language\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.\n* Conditions or drugs interfering with thyroid hormone uptake:\n* Patients with a history of atrophic gastritis\n* Patients using proton-pomp inhibitors","ALL","18 Years","75 Years",{"count":83,"type":84},40,"ESTIMATED","OBSERVATIONAL","This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.",[88,89,90,91,92],"Differentiated Thyroid Cancer","Thyroid Cancer","Levothyroxine","Liothyronine","Thyroid Hormones","NOT_YET_RECRUITING","2026-02-05",{"date":96,"type":97},"2026-02-10","ACTUAL",{"date":99,"type":84},"2026-09-01",{"date":101,"type":84},"2028-12-31",{"name":5,"class":6},2]